This study is interesting because it shows that higher intensity statins are more effective in reducing LDL-c, and by extension reduces CVD risk more than low-intermediate statins? This assumption has been used often (especially in Germany) to promote the idea that REDUCE-IT would have been less effective if all the patients were on high intensity statins.
However, we know from recent REDUCE-IT findings (ACC24 and others), that CVD RR is significant and consistent regardless of statin type or intensity or LDL-c levels. And… BTW regardless of TG or Lp(a) levels. All of this demonstrates that the MOA for VASCEPA® is along different pathways than traditional LLT’s.
Dare I say it again? “It’s the EPA stupid.” And the EPA/AA ratio.
News 
Market Data 
Discover 
